1. Home
  2. RDHL vs SNGX Comparison

RDHL vs SNGX Comparison

Compare RDHL & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

N/A

Current Price

$1.20

Market Cap

3.9M

Sector

Health Care

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$1.24

Market Cap

13.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RDHL
SNGX
Founded
2009
1987
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
RDHL
SNGX
Price
$1.20
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
75.2K
318.3K
Earning Date
09-05-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,550,000.00
N/A
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
157.62
N/A
52 Week Low
$1.01
$1.09
52 Week High
$7.43
$6.23

Technical Indicators

Market Signals
Indicator
RDHL
SNGX
Relative Strength Index (RSI) 45.49 33.35
Support Level $1.14 $1.55
Resistance Level $1.26 $1.70
Average True Range (ATR) 0.06 0.12
MACD 0.02 -0.01
Stochastic Oscillator 51.58 7.80

Price Performance

Historical Comparison
RDHL
SNGX

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: